| Typicality: | 0.344 |
| Saliency: | 0.220 |
| in 1999 | 3 | temporal |
| with the sole purpose | 3 | purpose |
| compound → be approved by → the fda | 5 |
| compound → be → fda-approved | 4 |
| negative | neutral | positive |
| 0.031 | 0.604 | 0.365 |
| Raw frequency | 9 |
| Normalized frequency | 0.220 |
| Modifier score | 0.500 |
| Perplexity | 133.066 |